Scott W G, Cooper B C, Scott H M
Infection. 1995;23 Suppl 1:S21-4. doi: 10.1007/BF02464955.
A cost-effectiveness study of roxithromycin versus amoxycillin/clavulanic acid using data from a 242 patient multicentre trial in Australia and New Zealand was undertaken in the general practice treatment of infections of the lower respiratory tract (LRTI). Those patients assigned to roxithromycin required on average 1 day less of treatment, significantly fewer extended courses of treatment, and fewer patients experienced side effects considered to be related to the treatment. The cost benefit (difference between the two treatment costs) per clinical success was A$17.04*. By substituting roxithromycin for amoxycillin/clavulanic acid, Australia would save A$ 1.704 million per 100,000 episodes of LRTI. The results demonstrate that savings in direct costs can be achieved by substituting roxithromycin for amoxycillin/clavulanic acid in the treatment of community-acquired LRTI.
利用澳大利亚和新西兰一项纳入242例患者的多中心试验数据，开展了一项关于罗红霉素与阿莫西林/克拉维酸治疗下呼吸道感染（LRTI）的成本效益研究。那些被分配接受罗红霉素治疗的患者平均治疗天数少1天，延长疗程的患者显著减少，且经历与治疗相关副作用的患者更少。每例临床治愈的成本效益（两种治疗成本之间的差值）为17.04澳元*。用罗红霉素替代阿莫西林/克拉维酸，澳大利亚每10万例LRTI发作可节省170.4万澳元。结果表明，在社区获得性LRTI的治疗中，用罗红霉素替代阿莫西林/克拉维酸可实现直接成本的节省。
